Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: Results from the non-interventional, single-cohort, multicentre, SUPRA study

Clinical Drug Investigation

Volumn 32, Issue 2, 2012, Pages 99-110

  Heidenreich, Stefan ^a   Leistikow, Frank ^a   Zinn, Stefan ^a   Baumann, Jörg ^a   Atzeni, Andreas ^b   Bajeski, Vitomir ^c   Dietzmann, Jörn ^d   Dragoun, Gert Peter ^e  

^a Praxis für Nieren und Hochdruckkrankheiten ^*  (Germany)

^b Dialysepraxis   (Germany)

^c Bielefelder Dialysezentrum   (Germany)

^d Praxis für Innere Medizin und Nephrologie   (Germany)

^e KfH Nierenzentrum   (Germany)

Author keywords

Anaemia; Erythropoiesis stimulants; Erythropoietin receptor agonists; Renal failure

Indexed keywords

ANTIHYPERTENSIVE AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CREATININE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

AGED; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BACKACHE; BARRETT ESOPHAGUS; BLISTER; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; EDEMA; ERYTHEMA; FEMALE; FERRITIN BLOOD LEVEL; FLU LIKE SYNDROME; FOLLOW UP; GERMANY; HEART DISEASE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIPHERAL EDEMA; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PRURITUS; RETINA HEMORRHAGE; RHINITIS; SIDE EFFECT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; GERMANY; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; REPRODUCIBILITY OF RESULTS;

EID: 84855458810     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11594040-000000000-00000     Document Type: Article

References (35)

1. McClellan W,Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20 (9): 1501-10 (Pubitemid 39361354)
2. Valderrabano F, Horl WH, Macdougall IC, et al. PREdialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18 (1): 89-100
3. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4 (1): 33-8
4. Fishbane S. Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 2008; 4 (4): 401-10
5. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69 (3): 560-4 (Pubitemid 43164450)
6. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19 (1): 121-32 (Pubitemid 38072623)
7. KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50 (3): 471-30
8. Locatelli F, Covic A, Eckardt KU, et al. ERA-EDTA ERBP Advisory Board Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24 (2): 348-54
9. Locatelli F, Covic A, Macdougall IC, et al., on behalf of the ORAMA Study Group. ORAMA: a study to investigate EBPG impact on renal anaemia. Design and baseline data. J Nephrol 2008; 21 (4): 592-603
10. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008; 13 (4): 393-404
11. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68 (3): 1337-43 (Pubitemid 43246455)
12. Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18 (12): 3164-70 (Pubitemid 350223976)
13. Rossert J, Gassmann-Mayer C, Frei D, et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22 (3): 794-800 (Pubitemid 46351687)
14. De Cock E, Van Bellinghen L, Standaert B. Assessing provider time for anaemia management of dialysis patients using time and motion methods: a multi-centre observational study in Europe [abstract]. Value Health 2002; 5: 581
15. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 2007; 82 (11): 1371-80 (Pubitemid 350060134)
16. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1 (6): 1211-5
17. Locatelli F, Villa G, de Francisco ALM, et al., on behalf of the BA16286 study investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 23 (5): 969-79 (Pubitemid 46799579)
18. Levin NW, Fishbane S, Canedo FV, et al., MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370 (9596): 1415-21 (Pubitemid 47576167)
19. Sulowicz W, Locatelli F, Ryckelynck JP, et al., PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2 (4): 637-46
20. Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 2011. Epub ahead of print
21. Macdougall IC, Walker R, Provenzano R, et al., ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3 (2): 337-47
22. Kessler M, Martinez-Castelao A, Siamopoulos KC, et al. C.E.R.A. once every 4 weeks in patients with chronic disease not on dialysis: the ARCTOS extension study. Hemodial Int 2010; 14 (2): 233-9
23. Drueke TB, Locatelli F, Clyne N, et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006; 335 (20): 2071-84 (Pubitemid 44749316)
24. Singh AK, SzczechL, Tang KL, et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006; 335 (20): 2085-98 (Pubitemid 44749317)
25. Horl WH. A need for an individualized approach to endstage renal disease patients. Nephrol Dial Transplant 2002; 17 Suppl. 6: 17-21 (Pubitemid 34823545)
26. Locatelli F, Aljama P, Canaud B, et al., Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Ara-nesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25 (9): 2846-50
27. Macdougall IC. Individualizing target haemoglobin concentrations: tailoring treatment for renal anaemia. Nephrol Dial Transplant 2001; 6 Suppl. 7: 9-14
28. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50 (6): 989-1000 (Pubitemid 350122810)
29. Spinowitz B, Coyne DW, Lok CE, et al., RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrology 2008; 28 (2): 280-9
30. Canaud B, Mingardi G, Braun J, et al., STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23 (11): 3654-61
31. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40 (1): 110-8 (Pubitemid 34701218)
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
33. Eckardt KU, Berns JS, Rocco MV, et al. Definition and classification of CKD: the debate should be about patient prognosis. A position statement from KDOQI and KDI-GO. Am J Kidney Dis 2009; 53 (6): 915-20
34. Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin treated hemodialysis patients. Kidney Int 2003; 64 (4): 1514-21 (Pubitemid 37153820)
35. Horl WH. Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002; 17 Suppl. 11: 35-8 (Pubitemid 35277062)